News
-
Quant Biomarkers AG partners with CHUV and UZH research teams and secures Innosuisse funding to advance clinically actionable cardio-kidney-metabolic biomarkers
More Details: Quant Biomarkers AG partners with CHUV and UZH research teams and secures Innosuisse funding to advance clinically actionable cardio-kidney-metabolic biomarkersBasel, Switzerland – January 2026 – Quant Biomarkers AG has secured approximately CHF 1 million in non-dilutive grant funding from Innosuisse to support the development and clinical validation of a biomarker test for earlier detection, progression assessment, and treatment monitoring of chronic kidney disease (CKD). The Innovation project supported by Innosuisse is advancing cutting-edge translational…